The purpose of this article is to illustrate the imaging findings of typical and atypical metastatic sites of recurrent endometrial carcinoma. Typical sites include local pelvic recurrence, pelvic and para-aortic nodes, peritoneum, and lungs. Atypical sites include extra-abdominal lymph nodes, liver, adrenals, brain, bones and soft tissue. It is important for radiologists to recognize the typical and atypical sites of metastases in patients with recurrent endometrial carcinoma to facilitate earlier diagnosis and treatment.
Introduction
Endometrial cancer is the most common gynecologic malignancy and accounts for 6% of all cancers in women. An estimated 43,470 cases are diagnosed with an estimated 7950 deaths in 2010 [1] . Endometrial carcinoma is divided into several histologic categories based on cell type. Endometrioid is the most common cell type, accounting for 7580% of cases, and subdivided into grade 1 (well differentiated) to grade 3 (poorly differentiated). Other aggressive pathologic variants with a high risk of metastatic disease include papillary serous carcinoma (510%), clear cell carcinoma (4%), squamous cell carcinoma (51%), mixed (10%) and undifferentiated types [2] . Local and distant recurrences continue to be a major problem in high-risk patients after surgical treatment of the primary endometrial carcinoma [3] . Adjuvant pelvic radiotherapy has been associated with decreased risk of local recurrence [4] . The median time of recurrence was 23 years and 7580% of recurrences were extra-pelvic. Recurrence is defined as local tumor regrowth or the development of distant metastasis discovered 6 months or more after complete regression of the treated tumor [5] .
Sixty-four percent of recurrences occur within 2 years and 87% of all recurrences occur by the third year after primary treatment [5] . Typical sites of recurrent endometrial carcinoma such as pelvic and para-aortic lymph nodes, vagina, peritoneum, and lungs are well recognized through various imaging modalities. Atypical sites such as intra-abdominal organs, bones, brain, abdominal wall, and muscle also occur. These less common patterns of recurrence are being recognized with greater frequency due to improvements in imaging techniques and prompt imaging of patients with suspected recurrence [6] . Some studies have shown that aggressive histopathologic types (such as papillary, clear cell, and adenosquamous) have mild higher incidence of relapse, with a higher incidence of extrauterine disease at presentation compared with the endometrioid type [2, 3] . In this article, we discuss and illustrate the spectrum of typical and atypical sites of recurrent endometrial carcinoma on computed tomography (CT), magnetic resonance imaging (MRI), and [
18 F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT. All the patients included in this review were treated for primary endometrial carcinoma, and referred for recurrence or relapse with histopathologic proof of local and distant recurrences.
Typical sites of recurrent endometrial carcinoma

Local recurrence
Local or pelvic recurrence in endometrial carcinoma is commonly seen in patients treated with adjuvant chemotherapy alone, and involves the vagina, pelvic nodes and to a lesser extent the cervix, adnexa, and peritoneum [7] . Isolated vaginal recurrence is most commonly seen in patients with stage 1 and 2 disease, in patients without adjuvant radiation therapy [8] . The most common location of recurrence within the vagina is the apex and middle vaginal canal, followed by the distal vagina, and suburethral area [8] (Fig. 1 ). Vaginal recurrence is also highly correlated with cervical involvement, whereas extravaginal pelvic recurrence 
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is correlated with deep myometrial and parametrial invasion and pelvic lymph nodes [5] . In general, patients with an isolated vaginal recurrence have a higher chance of cure than those with pelvic or abdominal recurrences, who in turn do better than those with distant metastases.
Pelvic and para-aortic nodal recurrence
Pelvic and para-aortic stations (Figs. 3 and 4) are most commonly involved in nodal spread from endometrial adenocarcinoma. The external iliac lymph nodes are most commonly involved pelvic lymph nodes in endometrial carcinoma, followed by the obturator and common iliac nodes [6] .
Peritoneal recurrence
Peritoneal carcinomatosis is one of the most typical sites of recurrent endometrial carcinoma, with 28% of relapses occurring in the peritoneum [6] . Peritoneal involvement may be seen as huge peritoneal masses (Fig. 2) , peritoneal nodules (Fig. 4) , and serosal implants that may cause extrinsic compression of the bowel. 
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Endometrial carcinoma has the highest frequency of pulmonary metastases compared with other gynecologic malignancies, up to 2025% [5, 6] . Although frequently multiple, bilateral nodules are seen (Fig. 6A) ; a solitary nodule mimicking primary lung cancer may also be seen (Fig. 5A) . Cavitation can be seen, especially with the squamous cell type. Lymphangitic carcinomatosis and endobronchial tumor spread are other pulmonary manifestations that are rarely seen (Fig. 7) . Pleural involvement in the form of effusions, nodularity and thickening is seen infrequently (Fig. 6B) .
Atypical sites of recurrent endometrial carcinoma
Extra-abdominal nodal disease
The incidence of isolated extra-abdominal nodal recurrences is uncommon (0.41% [9, 10] . Among these extraabdominal nodal sites, supraclavicular nodal recurrence has a higher incidence compared with mediastinal and axillary node involvement (Fig. 8) . Most supraclavicular and mediastinal recurrences were on the left side due to the location of the thoracic duct (Figs. 5A and 8 ).
Intra-abdominal organs
Compared with the typical metastatic sites such as the pelvic nodes, peritoneum, and lungs, the incidence of recurrent endometrial carcinoma is less frequent in intra-abdominal organs [5, 6] . It has been observed that aggressive pathologic types such as clear cell and papillary serous types are more prone to relapse in the abdomen, including the omentum [11] . The most common intra-abdominal solid organ involved is the liver (7%). Liver metastases are seen as single or multiple liver lesions with peripheral enhancement, and as a large solitary liver mass or lesion (Fig. 9) .The other atypical intraabdominal organs are the adrenal glands (Fig. 10) and spleen (1%) [6] .
Central nervous system metastases
Central nervous system involvement is rare (51%) [5, 6, 12] . Brain metastases may present as heterogeneously enhancing masses in cerebral and cerebellar regions. Lesions tend to have lobulated margins and may be hypointense on T1-and T2-weighted images (Figs. 5B,C and 6C) . Dural-based lesions with or without osseous involvement may also be seen (Fig. 11 ).
Musculoskeletal and soft tissue recurrence
The prevalence of osseous metastases in endometrial carcinoma ranges from 4% to 7% [5, 6, 13] . Endometrial metastases to the bone are generally restricted to the axial skeleton, including the pelvis and thoracolumbar vertebrae [13] (Fig. 13) . Skeletal metastases in the appendicular skeleton are very unusual. There are isolated case reports of unusual metastatic sites to extremities, such as the tibia, tarsus, calcaneus (Fig. 12) .
The prevalence of muscular and soft tissue metastases is 26% [6] (Fig. 14) . These manifest as enhancing Recurrent endometrial carcinoma 121 nodules or masses in the abdominal wall along the laparotomy scar or at remote locations (Fig. 15) .
Role of PET/CT in recurrent endometrial carcinoma
FDG-PET/CT is a highly sensitive, specific and useful modality for providing good anatomic and functional localization of sites of recurrence and distant metastasis in the preclinical stage before it becomes evident by conventional imaging modalities. PET/CT makes it possible to acquire both metabolic and anatomic imaging data and provides precise anatomic localization of suspicious areas of increased FDG uptake [9] . PET/CT may have the greatest usefulness in situations in which tumor marker levels are increasing and conventional imaging studies show negative results. Various studies have shown the percentage of cases in which clinical treatment was changed on the basis of PET/CT findings in patients with endometrial carcinoma with suspected recurrence and metastasis [14] .
Conclusions
Although some of the manifestations of recurrent endometrial carcinoma such as pelvic (vaginal), nodal, peritoneal and lung metastases are well known, other manifestations involving sites such as intra-abdominal organs (liver, adrenals, spleen), brain, osseous and soft tissue metastases are less well known. Aggressive histopathologic types such as clear cell and papillary serous types are more prone to relapse in atypical sites compared with endometrioid type. Advances in treatment options such as radiation therapy and chemotherapy are being made and as patients with recurrent endometrial carcinoma are imaged with greater frequency, the unusual and atypical sites of recurrent disease may be encountered more often.
